Dong-A ST’s ‘DA-9803’ transferred to U.S. NeuroBo
The Korea Drug Development Fund(President Hyun-Sang Mook, KDDF) announced the ‘Development of DA-9803, Natural Drug for the Treatment of Alzheimer’s Disease’ project that Dong-A ST has carried out has been transferred to U.S. NeuroBo Pharmaceuticals.
Dong-A ST’s ‘DA-9803,’ a medication for the t...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
